Blog
RSS FeedPosted by Michael Wonder on 25 Aug 2023
Public Summary Documents – May 2023 PBAC meeting
25 August 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2023 PBAC ...
Posted by Michael Wonder on 26 Jul 2023
ICER releases draft evidence report on treatment for metachromatic leukodystrophy
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
Posted by Michael Wonder on 20 Jul 2023
DUSC utilisation analysis public release documents (February 2023)
20 July 2023 - The utilisation analysis public release documents from the February 2023 DUSC meeting are now available. ...
Posted by Michael Wonder on 16 Jul 2023
Public summary documents (first time decisions not to recommend and deferrals) – March 2023 PBAC meeting
14 July 2023 - The public summary documents (first time decisions not to recommend and deferrals) from the March 2023 PBAC ...
Posted by Michael Wonder on 30 Jun 2023
Public summary documents – March 2023 PBAC meeting
30 June 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2023 PBAC ...
Posted by Michael Wonder on 24 May 2023
PBAC Public Summary Document - May 2023
24 May 2023 - The Public Summary Document of the PBAC's consideration of the interim report of the post-market review of ...
Posted by Michael Wonder on 17 Apr 2023
ICER publishes final evidence report on lecanemab for Alzheimer’s disease
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 06 Apr 2023
Public summary documents – December 2022 PBAC meeting
6 April 2023 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2022 PBAC ...
Posted by Michael Wonder on 22 Mar 2023
Advancing regulatory science in the EU – mid-point report published
22 March 2023 - The EMA has published a report summarising the mid-term achievements of its regulatory science strategy to ...
Posted by Michael Wonder on 19 Mar 2023
Public Summary Documents (first time decisions not to recommend and deferrals) - November 2022 PBAC meeting
17 March 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2022 PBAC ...
Posted by Michael Wonder on 03 Mar 2023
Public Summary Documents – November 2022 PBAC meeting (round 1)
3 March 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2022 PBAC ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...